|Bid||93.35 x 800|
|Ask||93.97 x 1400|
|Day's Range||92.47 - 94.08|
|52 Week Range||70.89 - 94.92|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||33.01|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||2.76 (3.05%)|
|Ex-Dividend Date||Mar 14, 2022|
|1y Target Est||95.73|
Pharmaceutical giant Merck & Co. is expanding its presence in Greater Boston, this time with nearly 160,000 additional square feet at its Bent Street facility in Cambridge, where it plans to hire another 100 or so people over the next few years.
Pharma stocks Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) have gained 23% and 5%, respectively, year to date. Merck had five blockbuster products in 2021, including the top-selling cancer drug in the world, Keytruda.
The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.